RU2015102067A - Активированная лейкоцитарная композиция - Google Patents

Активированная лейкоцитарная композиция Download PDF

Info

Publication number
RU2015102067A
RU2015102067A RU2015102067/15A RU2015102067A RU2015102067A RU 2015102067 A RU2015102067 A RU 2015102067A RU 2015102067/15 A RU2015102067/15 A RU 2015102067/15A RU 2015102067 A RU2015102067 A RU 2015102067A RU 2015102067 A RU2015102067 A RU 2015102067A
Authority
RU
Russia
Prior art keywords
cells
wound
composition according
composition
paragraphs
Prior art date
Application number
RU2015102067/15A
Other languages
English (en)
Russian (ru)
Inventor
Митчелл Ширван
Эйлат ШИНАР
Орит ФРЕНКЕЛЬ
Ади ЗУЛОФФШАНИ
Марина БУБИС
Эйлат БЭЙН
Ирэн ГИНИС
Original Assignee
Макрокьюэ, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Макрокьюэ, Лтд. filed Critical Макрокьюэ, Лтд.
Publication of RU2015102067A publication Critical patent/RU2015102067A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Surgery (AREA)
  • Materials Engineering (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
RU2015102067/15A 2009-03-05 2010-03-05 Активированная лейкоцитарная композиция RU2015102067A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20929809P 2009-03-05 2009-03-05
US61/209,298 2009-03-05
US21158709P 2009-04-01 2009-04-01
US61/211,587 2009-04-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2011139016/15A Division RU2548741C2 (ru) 2009-03-05 2010-03-05 Активированная лейкоцитарная композиция

Publications (1)

Publication Number Publication Date
RU2015102067A true RU2015102067A (ru) 2015-06-20

Family

ID=42710060

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2015102067/15A RU2015102067A (ru) 2009-03-05 2010-03-05 Активированная лейкоцитарная композиция
RU2011139016/15A RU2548741C2 (ru) 2009-03-05 2010-03-05 Активированная лейкоцитарная композиция

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2011139016/15A RU2548741C2 (ru) 2009-03-05 2010-03-05 Активированная лейкоцитарная композиция

Country Status (15)

Country Link
EP (2) EP2650001B1 (enExample)
JP (2) JP5713924B2 (enExample)
KR (1) KR101548783B1 (enExample)
CN (1) CN102438635B (enExample)
AU (1) AU2010220132B2 (enExample)
BR (1) BRPI1006759A2 (enExample)
CA (2) CA2867976A1 (enExample)
DK (1) DK2403509T3 (enExample)
ES (1) ES2428102T3 (enExample)
IL (1) IL214953A0 (enExample)
MX (1) MX2011009277A (enExample)
PL (1) PL2403509T3 (enExample)
RU (2) RU2015102067A (enExample)
WO (1) WO2010100570A2 (enExample)
ZA (1) ZA201107269B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8574902B2 (en) 2009-03-05 2013-11-05 Macrocure Ltd. Activated leukocyte composition and uses for wound healing
BR112013005610A2 (pt) * 2010-09-09 2019-09-24 Macrocure Ltd sobrenadante condicionado de leucócito, alcs, método para o tratamento de uma ferida, método para a inibição do surgimento de infecção em uma ferida, método, sobrenadante e produto
WO2013136182A1 (en) 2012-03-15 2013-09-19 Macrocure, Ltd. Activated immunostimulatory cell composition and uses thereof
RU2014140795A (ru) 2012-03-15 2016-05-10 Макрокьюэ, Лтд. Активированная иммуностимулирующая клеточная композиция, используемая для лечения инфекционных заболеваний
EP2781224A1 (en) * 2013-03-18 2014-09-24 Khorionyx Implantable preparations comrpsing globin insoluble at physiological pH and serum for regeneration of tissues and treatment of wounds.
CN107427535A (zh) 2015-02-16 2017-12-01 纳雅康医疗有限公司 经修饰的血凝块
GB201618106D0 (en) 2016-10-26 2016-12-07 Lift Biosciences Ltd Cancer-killing cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60120821A (ja) * 1983-12-05 1985-06-28 Asahi Chem Ind Co Ltd 悪性腫瘍治療用白血球刺激材および刺激方法
US4751001A (en) * 1984-09-24 1988-06-14 Becton Dickinson And Company Blood partitioning apparatus
JPH02167071A (ja) * 1988-12-19 1990-06-27 Terumo Corp 非ヒト動物由来白血球系細胞の分離材、分離器および分離方法
JPH07102151B2 (ja) * 1994-06-03 1995-11-08 中外製薬株式会社 新規なポリペプチドの製造法
IL110195A (en) * 1994-07-03 2003-10-31 David Danon Method and system for cultivating macrophages
US6146890A (en) 1994-07-03 2000-11-14 Danon; David Method and system for cultivating macrophages
JP3201610B2 (ja) * 1995-03-17 2001-08-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 腫瘍を処置する方法
JPH10259134A (ja) * 1997-01-16 1998-09-29 Sekisui Chem Co Ltd 創傷治癒促進剤
RU2143685C1 (ru) * 1998-05-19 1999-12-27 Коган Александр Харитонович Способ дифференциального подсчета гранулоцитов, моноцитов и лимфоцитов
EP1731175B1 (en) * 1998-11-12 2009-09-30 International Manufacturing Group, Inc. Hemostatic cross-linked dextran beads useful for rapid blood coagulation and hemostatis
AU2002353465B2 (en) * 2001-11-21 2008-10-16 Yeda Research And Development Co. Ltd. Process for the manufacture of human mononuclear phagocytic leukocytes
JP4108393B2 (ja) * 2002-07-15 2008-06-25 テルモ株式会社 細胞増殖剤の製造方法
JP4245324B2 (ja) * 2002-10-09 2009-03-25 旭化成クラレメディカル株式会社 単球の分離回収方法
EP2198873A1 (en) * 2008-12-18 2010-06-23 Aposcience AG Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture
EP2201954A1 (en) * 2008-12-18 2010-06-30 Aposcience AG Pharmaceutical preparation

Also Published As

Publication number Publication date
RU2011139016A (ru) 2013-04-10
KR101548783B1 (ko) 2015-08-31
WO2010100570A3 (en) 2010-12-16
RU2548741C2 (ru) 2015-04-20
CA2754190A1 (en) 2010-09-10
JP2015129180A (ja) 2015-07-16
EP2403509B1 (en) 2013-08-21
ZA201107269B (en) 2014-03-26
CA2867976A1 (en) 2010-09-10
EP2403509A2 (en) 2012-01-11
DK2403509T3 (da) 2013-09-16
WO2010100570A2 (en) 2010-09-10
KR20120002530A (ko) 2012-01-05
EP2650001A1 (en) 2013-10-16
CN102438635A (zh) 2012-05-02
BRPI1006759A2 (pt) 2016-03-15
CN102438635B (zh) 2014-09-17
AU2010220132A1 (en) 2011-10-13
JP5713924B2 (ja) 2015-05-07
AU2010220132B2 (en) 2013-10-10
IL214953A0 (en) 2011-11-30
EP2650001B1 (en) 2016-09-07
ES2428102T3 (es) 2013-11-05
MX2011009277A (es) 2011-12-16
PL2403509T3 (pl) 2013-11-29
JP2012519681A (ja) 2012-08-30

Similar Documents

Publication Publication Date Title
Driver et al. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers
Lord et al. Mobilization of early hematopoietic progenitor cells with BB-10010: A genetically engineered variant of human macrophage inflammatory protein-la
Carter et al. Use of platelet rich plasma gel on wound healing: a systematic review and meta-analysis
Chandika et al. Marine-derived biological macromolecule-based biomaterials for wound healing and skin tissue regeneration
Whelan et al. Mechanics of wound healing and importance of vacuum assisted closure® in urology
RU2011139016A (ru) Активированная лейкоцитарная композиция
Xiong et al. Hesperidin-loaded self-assembled supramolecular hydrogel based on quaternized chitosan as efficient photothermal antibacterial dressing for MRSA-infected wound healing
JP2012519681A5 (enExample)
Bolwell et al. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial
CN103990174B (zh) 一种强力吸液引流敷料及其制备方法和吸液引流装置
CN110623792B (zh) 一种医学敷料及其制备方法
Rhodes et al. Allogeneic peripheral blood stem cell collection as of 2008
JP2015047125A (ja) マクロファージの分化誘導剤およびそれを用いるマクロファージの分化誘導方法
RU2007114366A (ru) Перевязочный материал для ухода за раной и способ его использования
EP3400916A1 (en) Adhesive covering structure
Noguerado-Mellado et al. Anaphylactic shock due to brentuximab-vendotin confirmed by skin test and in vitro tests
CN1481811A (zh) 聚丙烯酸钠、羧甲基纤维素接枝聚丙烯酸制备作为止血剂
El-Badawi et al. Impact of topical heparin on healing of skin graft donor site in burn patients
DE102014211356A1 (de) Wundkontaktmaterial zur Anwendung bei der Behandlung und/oder Versorgung von Wunden
CN204864217U (zh) 一种新型止血材料
CN1292755C (zh) 羧甲基纤维素接枝聚丙烯酸的应用及止血材料
Sekiguchi et al. Changes in donor apheresis in Japan
Alkhazraji et al. Therapeutic use of honey for skin wounds healing in Iraqi awassi sheep
Greenhalgh et al. 521 A Randomized Trial Comparing a Transparent Biosynthetic Wound Matrix to Silver-foam Dressing for Partial-thickness Burns
Eckert et al. 861 Treatment of Full-Thickness Burns with Biodegradable Polyurethane Matrix and Autologous Skin Cell Suspension: Case Series

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20180129